These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37262007)

  • 21. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cohort profile: A Québec-based plasma donor biobank to study COVID-19 immunity (PlasCoV).
    Germain M; Lewin A; Bazin R; Dieudé M; Perreault J; Boivin A; Grégoire Y; Renaud C
    BMJ Open; 2023 Feb; 13(2):e068803. PubMed ID: 36822809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Social Vulnerability and Rurality Associated With Higher Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection-Induced Seroprevalence: A Nationwide Blood Donor Study-United States, July 2020-June 2021.
    Li Z; Lewis B; Berney K; Hallisey E; Williams AM; Whiteman A; Rivera-González LO; Clarke KEN; Clayton HB; Tincher T; Opsomer JD; Busch MP; Gundlapalli AV; Jones JM
    Clin Infect Dis; 2022 Aug; 75(1):e133-e143. PubMed ID: 35137014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
    Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
    JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
    Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
    Bobrovitz N; Ware H; Ma X; Li Z; Hosseini R; Cao C; Selemon A; Whelan M; Premji Z; Issa H; Cheng B; Abu Raddad LJ; Buckeridge DL; Van Kerkhove MD; Piechotta V; Higdon MM; Wilder-Smith A; Bergeri I; Feikin DR; Arora RK; Patel MK; Subissi L
    Lancet Infect Dis; 2023 May; 23(5):556-567. PubMed ID: 36681084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
    Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare workers highly affected during the COVID-19 epidemic wave in Poland prior to vaccination availability: seroprevalence study.
    Rosińska M; Stępień M; Kitowska W; Milczarek M; Juszczyk G; Nowacka Z; Gardel A; Hermann A; Bardoń-Błaszkowska A; Cudnik R; Czubak H; Wolniak-Bińkowska M; Źródłowska IA; Sadkowska-Todys M
    Med Pr; 2022 Apr; 73(2):109-123. PubMed ID: 35301511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
    Angulo FJ; Finelli L; Swerdlow DL
    JAMA Netw Open; 2021 Jan; 4(1):e2033706. PubMed ID: 33399860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
    Johnson AG; Linde L; Ali AR; DeSantis A; Shi M; Adam C; Armstrong B; Armstrong B; Asbell M; Auche S; Bayoumi NS; Bingay B; Chasse M; Christofferson S; Cima M; Cueto K; Cunningham S; Delgadillo J; Dorabawila V; Drenzek C; Dupervil B; Durant T; Fleischauer A; Hamilton R; Harrington P; Hicks L; Hodis JD; Hoefer D; Horrocks S; Hoskins M; Husain S; Ingram LA; Jara A; Jones A; Kanishka FNU; Kaur R; Khan SI; Kirkendall S; Lauro P; Lyons S; Mansfield J; Markelz A; Masarik J; McCormick D; Mendoza E; Morris KJ; Omoike E; Patel K; Pike MA; Pilishvili T; Praetorius K; Reed IG; Severson RL; Sigalo N; Stanislawski E; Stich S; Tilakaratne BP; Turner KA; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(6):145-152. PubMed ID: 36757865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021.
    Jones JM; Opsomer JD; Stone M; Benoit T; Ferg RA; Stramer SL; Busch MP
    JAMA; 2022 Jul; 328(3):298-301. PubMed ID: 35696249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022.
    Yamayoshi S; Iwatsuki-Horimoto K; Okuda M; Ujie M; Yasuhara A; Murakami J; Duong C; Hamabata T; Ito M; Chiba S; Kobayashi R; Takahashi S; Mitamura K; Hagihara M; Shibata A; Uwamino Y; Hasegawa N; Ebina T; Izumi A; Kato H; Nakajima H; Sugaya N; Seki Y; Iqbal A; Kamimaki I; Yamazaki M; Kawaoka Y; Furuse Y
    Emerg Infect Dis; 2022 Nov; 28(11):2198-2205. PubMed ID: 36198306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating immunity to SARS-CoV-2 in nursing home residents using saliva IgG.
    Katz MJ; Heaney CD; Pisanic N; Smith L; Bigelow BF; Sheikh F; Boudreau A; Kruczynski K; Hsu YJ; Salinas AB; Cosgrove SE; Rock C
    J Am Geriatr Soc; 2022 Mar; 70(3):659-668. PubMed ID: 35038344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.
    Bajema KL; Wiegand RE; Cuffe K; Patel SV; Iachan R; Lim T; Lee A; Moyse D; Havers FP; Harding L; Fry AM; Hall AJ; Martin K; Biel M; Deng Y; Meyer WA; Mathur M; Kyle T; Gundlapalli AV; Thornburg NJ; Petersen LR; Edens C
    JAMA Intern Med; 2021 Apr; 181(4):450-460. PubMed ID: 33231628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
    Nordström P; Ballin M; Nordström A
    Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.